Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families

Journal of the National Cancer Institute

Volumn 96, Issue 10, 2004, Pages 785-795

  Chaudru, Valérie ^a   Chompret, Agnès ^b   Bressac de Paillerets, Brigitte ^b   Spatz, Alain ^b   Avril, Marie Françoise ^b   Demenais, Florence ^a  

^a UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2;

ARTICLE; CANCER MODEL; CANCER SUSCEPTIBILITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DYSPLASTIC NEVUS; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; MELANOMA; NEVUS; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SEGREGATION ANALYSIS; SKIN PIGMENTATION; SKIN SENSITIVITY; STATISTICAL SIGNIFICANCE; SUN EXPOSURE; SUNBURN; ADULT; AGED; FRANCE; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; RISK; RISK ASSESSMENT; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN TUMOR; STATISTICAL MODEL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CONFIDENCE INTERVALS; FEMALE; FRANCE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LINKAGE (GENETICS); LOGISTIC MODELS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEVUS; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; SKIN PIGMENTATION; SUNBURN;

EID: 2942683037     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh136     Document Type: Article

References (47)

1. Fountain JW, Bale SJ, Housman DE, Dracopoli NC. Genetics of melanoma. Cancer Surv 1990;9:645-71.
2. Greene MH, Fraumeni JF. The hereditary variant of malignant melanoma. New York (NY): Grune and Stratton; 1979.
3. Greene MH, Goldin LR, Clark WH Jr., Lovrien E, Kraemer KH, Tucker MA, et al. Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A 1983;80: 6071-5.
4. Risch N, Sherman S. Genetic Analysis Workshop 7: summary of the melanoma workshop. Cytogenet Cell Genet 1992;59:148-58.
5. Aitken JF, Bailey-Wilson J, Green AC, MacLennan R, Martin NG. Segregation analysis of cutaneous melanoma in Queensland. Genet Epidemiol 1998;15:391-401.
6. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366: 704-7.
7. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995;267:249-52.
8. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
9. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998;7:209-16.
10. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000;92:1006-10.
11. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9.
12. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66:176-86.
13. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001;117:294-300.
14. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001;69: 774-9.
15. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997;73:198-203.
16. Armstrong BK, English DR. Cutaneous malignant melanoma. In D. Schottenfeld and J.F. Fraumeni J, editor. Cancer epidemiology and prevention. 2 ed. New York (NY): Oxford University Press; 1996. pp. 1282-312.
17. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. Jama 1997;277:1439-44.
18. Elwood JM, Whitehead SM, Davison J, Stewart M, Gait M. Malignant melanoma in England: risks associated with naevi, freckles, social class, hair colour, and sunburn. Int J Epidemiol 1990;19:801-10.
19. Osterlind A, Tucker MA, Hou-Jensen K, Stone BJ, Engholm G, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. I. Importance of host factors. Int J Cancer 1988;42:200-6.
20. Goldstein AM, Martinez M, Tucker MA, Demenais F. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families. Cancer Epidemiol Biomarkers Prev 2000;9: 889-94.
21. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
22. Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765-73.
23. Burke W, Austin MA. Genetic risk in context: calculating the penetrance of BRCA1 and BRCA2 mutations. J Natl Cancer Inst 2002;94:1185-7.
24. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002;94:1221-6.
25. Grange F, Chompret A, Guilloud-Bataille M, Guillaume JC, Margulis A, Prade M, et al. Comparison between familial and nonfamilial melanoma in France. Arch Dermatol 1995;131:1154-9.
26. Briollais L, Chompret A, Guilloud-Bataille M, Feingold N, Avril MF, Demenais F. Genetic and epidemiological risk factors for a malignant melanoma-predisposing phenotype: the great number of nevi. Genet Epidemiol 1996;13:385-402.
27. Bonney GE. Regressive logistic models for familial disease and other binary traits. Biometrics 1986;42:611-25.
28. Abel L, Bonney GE. A time-dependent logistic hazard function for modeling variable age of onset in analysis of familial diseases. Genet Epidemiol 1990;7:391-407.
29. Bonney GE, Lathrop GM, Lalouel JM. Combined linkage and segregation analysis using regressive models. Am J Hum Genet 1988;43:29-37.
30. Elston RC, Stewart J. A general model for the genetic analysis of pedigree data. Hum Hered 1971;21:523-42.
31. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995; 142:1255-64.
32. Chaudru V, Laing A, Dunston GM, Adams-Campbell LL, Williams R, Lynch JJ, et al. Interactions between genetic and reproductive factors in breast cancer risk in a population-based sample of African-American families. Genet Epidemiol 2002;22:285-97.
33. Elston RC, Sobel E. Sampling considerations in the gathering and analysis of pedigree data. Am J Hum Genet 1979;31:62-9.
34. Hodge SE, Elston RC. Lods, wrods, and mods: the interpretation of lod scores calculated under different models. Genet Epidemiol 1994;11:329-42.
35. Martinez M, Goldstein A, O'Connell J. Comparison of likelihood approaches for combined segregation and linkage analysis of a complex disease and a candidate gene marker under different ascertainment schemes. Genet Epidemiol 2001;21 Suppl 1:S760-5.
36. Demenais F, Lathrop M. REGRESS: a computer program including the regressive approach into the LINKAGE programs. Genet Epidemiol 1994; 11:291.
37. Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998;11:1-3.
38. Ménégoz F, Chérié-Challine L, editors. Le Cancer en France: Incidence et Mortalité. Situation en 1995. Evolution entre 1975 et 1995. Réseau Francim et Direction Générale de la Santé, Ministère de l'Emploi et de la Solidarité. La Documentation Française, 1998.
39. Albino AP, Fountain JW. Oncogenes and tumor suppressor genes in cutaneous malignant melanoma. Photochem Photobiol 1996;63:412-8.
40. Gibbs P, Brady BM, Robinson WA. The genes and genetics of malignant melanoma. J Cutan Med Surg 2002;6:229-35.
41. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
42. Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 1995;5:169-77.
43. Wachsmuth RC, Harland M, Bishop JA. The atypical-mole syndrome and predisposition to melanoma. N Engl J Med 1998;339:348-9.
44. Tucker MA, Fraser MC, Goldstein AM, Struewing JP, Icing MA, Crawford JT, et al. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer 2002;94:3192-209.
45. Briollais L, Chompret A, Guilloud-Bataille M, Bressac-de Paillerets B, Avril MF, Demenais F. Patterns of familial aggregation of three melanoma risk factors: great number of naevi, light phototype and high degree of sun exposure. Int J Epidemiol 2000;29:408-15.
46. Siskind V, Aitken J, Green A, Martin N. Sun exposure and interaction with family history in risk of melanoma, Queensland, Australia. Int J Cancer 2002;97:90-5.
47. Sturm RA. Skin colour and skin cancer - MC1R, the genetic link. Melanoma Res 2002;12:405-16.